Table 2.
Relative content of human derived ATIICs and ATICs in BLM-mouse lung tissue
| SPC+ | Nuclei+ (#) | SPC+/Nuclei+ | SPC+/Nuclei− | SPC−/Nuclei+ | SPC+ Nuclei+ (%*) | SPC−Nuclei+ (%**) | |
|---|---|---|---|---|---|---|---|
| Saline-SCID | 500.0 | - | - | 500.0 | - | - | - |
| BLM-SCID | 100.0 | - | - | 100.0 | - | - | - |
| BLM-SCID/Monos | 100.0 | - | - | 100.0 | - | - | - |
| BLM-SCID/ATIICs | 500.0 | 232.0 ± 4.8 | 137.0 ± 4.0 (59.1%)a | 363.0 ± 4 | 95 ± 8.6 (40.9%)b | 37.74 ± 1.5 | 69.5 ± 8.2 |
SPC+: ATIICs (mouse and human ATIICs)
Nuclei+: human derived cells
SPC+/Nuclei+: hiPSC-ATIICs
SPC+/Nuclei−: mouse ATIICs
#
number of nuclei+ cells in the counted area of 500 SPC+ cells
%*
ratio of hiPSC-ATIICs to mouse ATIICs, %**: ratio of SPC− human cells to hiPSC-ATIICs
a
ratio of hiPSC-ATIICs to human derived cells,
b
ratio of SPC− human cells to human derived cells